1. < Pancreatic Cancer

New biomarker Claudin 18.2

Posted by marienewland @mnewland99, Mar 17 11:22am

From these posts on this site I've noticed that there are a few pancan members (including me) who also have nodules/tumors in the abdominal peritoneum. There is a new biomarker Claudin 18.2 that can detect these little rascals for related cancers in the gastric area. Early detection is always a plus and the industry is always looking for drugs to target these proteins. My oncologist has ordered a test for me so I should know in the near future whether I test positive for it.

Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.

marienewland | @mnewland99 | Mar 29 1:31pm

Good to know Mark about the PARPIs. I haven’t seen articles or studies with that info yet. I did read they are using the PARPIs on ATM. Have you read or do you know if all of these trials are treated on Murine (fancy word for mice, I think) population which must have some proven success?
I am looking forward to KRAS12D clinical trials also!

REPLY
1 reply
marienewland | @mnewland99 | Mar 29 1:38pm
In reply to @stageivsurvivor "KRAS, CHEK2 and ATM are entirely different pathways. The RAS/KRAS pathway of cell signaling is involved..." + (show)
@stageivsurvivor

KRAS, CHEK2 and ATM are entirely different pathways. The RAS/KRAS pathway of cell signaling is involved with cell growth and proliferation. CHEK2 and ATM serve different functions regarding DNA.

PARP inhibitors such as Olaparib, Rucaparib and Niraparib are being looked at in ATM and CHEK2 mutations.

KRAS G12D has a number of targeted therapies in clinical trials presently including MRTX1133, HRS-4642, and RMC-9805. Eli Lilly has a vaccine targeting KRAS in a phase II trial called ELI-002. The AMPIFY-201 trial is also looking promising.

Just above the G12 variations in the cell signaling path for RAS/KRAS/RAF/MEK/ERK is the RAS gene which serves as a master ON/OFF switch for cell growth and proliferation. The mutation causing uncontrolled growth causes the switch to be stuck in the “ON” position. There are a couple of trials for drugs considered a “pan” KRAS targeting small molecule drug designed to turn the RAS Master switch to OFF. RMC6236 and RSC-1255 are two trials underway.

Jump to this post

Do you know if they test these clinicals or vaccines on the murine population with success, first?

Thank you for your thorough response!

REPLY
marienewland | @mnewland99 | Mar 29 1:40pm
In reply to @mnewland99 "Good to know Mark about the PARPIs. I haven’t seen articles or studies with that info..." + (show)
@mnewland99

Good to know Mark about the PARPIs. I haven’t seen articles or studies with that info yet. I did read they are using the PARPIs on ATM. Have you read or do you know if all of these trials are treated on Murine (fancy word for mice, I think) population which must have some proven success?
I am looking forward to KRAS12D clinical trials also!

Jump to this post

Also stageiv do you know anything about the CLDN18.2 protein for pancreatic cancer?
Thank you.

REPLY
View MoreView Less
Please sign in or register to post a reply.